---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-029057"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:29:52.841138+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance reports $485M cash, AMTAGVI launch ongoing; partial clinical hold on lung TIL trial

## Summary
- Cash position ~$485M as of 2/22/24, including $197.1M from Feb 2024 equity offering.
- AMTAGVI (lifileucel) approved for advanced melanoma; 30 active ATCs at launch, targeting ~50 within 90 days.
- FDA placed partial clinical hold on IOV-LUN-202 NSCLC trial on Dec 22, 2023; enrollment paused.
- Phase 3 TILVANCE-301 frontline melanoma trial randomized first patient in 2Q23.
- Proleukin acquired for £167.7M upfront; global rights secured for IL-2 supply in AMTAGVI regimen.

## SEC filing metadata
- accession: 0001104659-24-029057
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924029057/0001104659-24-029057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924029057/tm247560d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-029057
- JSON: https://secwatch.observer/filing/0001104659-24-029057.json
- Plain text: https://secwatch.observer/filing/0001104659-24-029057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.